Prof D van der Windt, Prof K Jordan
No more applications being accepted
Funded PhD Project (European/UK Students Only)
About the Project
The Institute for Primary Care and Health Sciences (iPCHS) is the largest and most successful Research Institute at Keele (http://www.keele.ac.uk/pchs/). It is dedicated to undertake research that will improve the quality and content of primary care for arthritis, chronic musculoskeletal pain and associated comorbidities. It hosts the Arthritis Research UK Primary Care Centre-of-Excellence, is a current member of the NIHR School for Primary Care Research and holds the Queen’s Anniversary Prize for Pioneering the early prevention and treatment of chronic pain. 91% of Keele’s research in Primary Care has been judged world leading or internationally excellent (Ref 2014)
Aims: The overall aim of this project is to better understand the influence of new onset of musculoskeletal pain, or changes in the severity of existing pain, on health and disease outcomes in people with existing long-term conditions.
Objectives & methods: The PhD project will include 3 phases: (1) a systematic review will be conducted to summarize evidence from existing studies regarding the influence of pain on future general health outcomes in people with multimorbidity; (2) data from our existing our cohort studies will then be used to investigate the longitudinal associations between musculoskeletal pain and health outcomes in people with multimorbidity; and (3) electronic health records will be analysed to explore the role of new onset musculoskeletal pain in predicting future disease outcomes in a more specific subgroup, e.g. patients with COPD.
Funding Notes
All fees paid at current UK/EU rates, for three years only
Stipend paid at current Research Council rate, for three years full time or six years part time.
Fees provided at EU rates only, Non-EU students would be required to pay the additional overseas fees themselves. Fees will only be paid for three years full time or six years part time
Continue with Facebook
